Skip to main content
OpenTrials
Completed

NCT Number: NCT00000274

Flupenthixol and Haloperidol for Treating Cocaine Abuse Schizophrenics - 9

The purpose of this study is to evaluate the safety and efficacy of flupenthixol and haloperidol for cocaine dependence in individuals with schizophrenia/schizoaffective illness.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cocaine-Related Disorders Chemically-Induced Disorders Mental Disorders Substance-Related Disorders

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

New York State Psychiatric Institute

New York, 10032, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Please contact site for information.

Treatment and study plan

Flupenthixol

Drug

Primary outcomes

  1. Side effects

  2. Drug use

  3. Psychiatric symptoms

  4. Cocaine craving

Sponsors and collaborators

Lead sponsor

National Institute on Drug Abuse (NIDA)

Nih

Collaborators

  • New York State Psychiatric Institute

Registry information

Official study title

Flupenthixol and Haloperidol for Treating Cocaine Abuse Schizophrenics

Important dates

Study start
1997
Study completion
1999
First posted
Sep 21, 1999
Registry last updated
Jan 12, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.